Woffendin C, Plagemann P G
Department of Microbiology, Medical School, University of Minnesota, Minneapolis 55455.
J Membr Biol. 1987;98(1):89-100. doi: 10.1007/BF01871048.
Equilibrium binding of [3H]dipyridamole identified high-affinity (Kd approximately 10 nM) binding sites on human erythrocytes (approximately 5 X 10(5) sites/cell) and on HeLa cells (approximately 5 X 10(6) sites/cell). The equilibration of dipyridamole with these sites on human erythrocytes was compatible with a second-order process which proceeded at 22 degrees C with a rate constant of about 6 X 10(6) M-1 sec-1. Binding of dipyridamole to these sites correlated kinetically with the inhibition of the equilibrium exchange of 500 microM uridine in these cells and was inhibited in a concentration-dependent manner by nucleosides and other inhibitors of nucleoside transport, such as nitrobenzylthioinosine, dilazep and lidoflazine, but not by hypoxanthine, which is not a substrate for the nucleoside transporter of human erythrocytes. The results indicate that the substrate binding site of the transporter is part of the high-affinity dipyridamole binding site. Bound [3H]dipyridamole became displaced from these sites on human erythrocytes by incubation with an excess of unlabeled dipyridamole or high concentrations of nucleosides and inhibitors of nucleoside transport, but neither by hypoxanthine nor sugars. Dissociation of [3H]dipyridamole behaved as a simple first-order process, but the rate constant was about one order of magnitude lower (about 3 X 10(-3) sec-1) than anticipated for typical ligand-protein binding on the basis of the measured association rate and equilibrium constants. The reason for this discrepancy has not been resolved. No high-affinity dipyridamole binding sites were detected on Novikoff rat hepatoma cells, P388, L1210 and S49 mouse leukemia cells or Chinese hamster ovary cells, and their absence correlated with a greater resistance of nucleoside transport in these cells to inhibition by dipyridamole. All cells expressed considerable low affinity (Kd greater than 0.5 microM) and nonspecific binding of dipyridamole.
[3H]双嘧达莫的平衡结合确定了人红细胞(约5×10⁵个位点/细胞)和HeLa细胞(约5×10⁶个位点/细胞)上的高亲和力(Kd约为10 nM)结合位点。双嘧达莫与人红细胞上这些位点的平衡符合二级反应过程,该过程在22℃下进行,速率常数约为6×10⁶ M⁻¹秒⁻¹。双嘧达莫与这些位点的结合在动力学上与这些细胞中500 μM尿苷平衡交换的抑制相关,并且被核苷和其他核苷转运抑制剂(如硝基苄硫肌苷、双嘧达莫酯和利多氟嗪)以浓度依赖性方式抑制,但不被次黄嘌呤抑制,次黄嘌呤不是人红细胞核苷转运体的底物。结果表明,转运体的底物结合位点是高亲和力双嘧达莫结合位点的一部分。通过与过量未标记的双嘧达莫或高浓度的核苷及核苷转运抑制剂孵育,结合在人红细胞这些位点上的[3H]双嘧达莫会被取代,但次黄嘌呤和糖类不会。[3H]双嘧达莫的解离表现为简单的一级反应过程,但速率常数比根据测得的缔合速率和平衡常数预期的典型配体 - 蛋白质结合低约一个数量级(约3×10⁻³秒⁻¹)。这种差异的原因尚未解决。在诺维科夫大鼠肝癌细胞、P388、L1210和S49小鼠白血病细胞或中国仓鼠卵巢细胞上未检测到高亲和力双嘧达莫结合位点,它们的缺失与这些细胞中核苷转运对双嘧达莫抑制的更大抗性相关。所有细胞均表现出双嘧达莫的相当程度的低亲和力(Kd大于0.5 μM)和非特异性结合。